Showing results (271-280 of 1,297) with videos related to
Sort By:
Pageof 130
Circulation|March 13, 2018
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS ProgramKarin Rådholm, Gemma Figtree, Vlado Perkovic, et al.Journal of Cardiac Failure|April 18, 2020
Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours HemodialysisBrendan Smyth, Christopher T Chan, Stuart M Grieve, et al.Kidney International Reports|July 9, 2025
Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFRDana Kim, Brendon L Neuen, Jicheng Lv, et al.Journal of the American Society of Nephrology : JASN|July 23, 2020
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS ProgramMegumi Oshima, Bruce Neal, Tadashi Toyama, et al.The Lancet. Diabetes & Endocrinology|November 11, 2018
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trialDick de Zeeuw, Ronny W Renfurm, George Bakris, et al.Diabetes, Obesity & Metabolism|January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trialBruce Neal, Vlado Perkovic, David R Matthews, et al.Circulation|August 30, 2024
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Lauren Heath, et al.Kidney International Reports|July 31, 2024
The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A NephropathyDana Kim, Jicheng Lv, Michelle Hladunewich, et al.Diabetes Care|March 13, 2020
Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 StudyLouisa Sukkar, Amy Kang, Carinna Hockham, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 18, 2015
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled TrialGreg Fulcher, David R Matthews, Vlado Perkovic, et al.Pageof 130